Zealand Pharma (DB:22ZA) - Cotización, noticias y análisis

Resumen de acción 22ZA

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark.

Acerca de la empresa

22ZA fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Recompensas

Cotiza un 79.8% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 97.02%

Análisis de riesgos

Acciones altamente ilíquidas

Los accionistas han sido diluidos en el último año

Tiene menos de 1 año de cash runway

Competidores de Zealand Pharma A/S

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€682.6m

MorphoSys

XTRA:MOR

€2.6b

Heidelberg Pharma

XTRA:HPHA

€139.8m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Zealand Pharma
Historical stock prices
Current Share Price	kr.17.10
52 Week High	kr.21.00
52 Week Low	kr.9.20
Beta	1.01
1 Month Change	0%
3 Month Change	3.64%
1 Year Change	-6.56%
3 Year Change	-44.82%
5 Year Change	n/a
Change since IPO	51.17%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	22ZA	DE Biotechs	Mercado DE
7D	0%	-5.1%	-2.0%
1Y	-6.6%	-21.1%	-0.3%

Rentabilidad vs. Industria: 22ZA superó al sector German Biotechs , que obtuvo un rendimiento del -23.1% el año pasado.

Rentabilidad vs. Mercado: 22ZA obtuvo unos resultados inferiores a los del mercado German, que fue del 5.9% el año pasado.

Volatilidad de los precios

Is 22ZA's price volatile compared to industry and market?
22ZA volatility
22ZA Average Weekly Movement	n/a
Biotechs Industry Average Movement	5.0%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.0%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: 22ZA no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de 22ZA en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1997	203	Adam Steensberg	www.zealandpharma.com

Resumen de fundamentos de Zealand Pharma A/S

¿Cómo se comparan los beneficios e ingresos de Zealand Pharma con su capitalización de mercado?
Estadísticas fundamentales de 22ZA
Capitalización bursátil	€1.36b
Beneficios(TTM)	-€150.45m
Ingresos (TTM)	€37.33m

36.3x

Ratio precio-ventas (PS)

-9.0x

Ratio precio-beneficio (PE)

¿Está 22ZA sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de 22ZA
Ingresos	kr.277.51m
Coste de los ingresos	kr.108.42m
Beneficio bruto	kr.169.09m
Otros gastos	kr.1.29b
Beneficios	-kr.1.12b

Últimos beneficios comunicados

Sep 30, 2022

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-21.73
Margen bruto	60.93%
Margen de beneficio neto	-403.04%
Ratio deuda/patrimonio	100.6%

¿Cómo se ha desempeñado 22ZA a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción 22ZA

Recompensas

Análisis de riesgos

Competidores de Zealand Pharma A/S

XTRA:BIO3

€1.4b

XTRA:FYB

€682.6m

XTRA:MOR

€2.6b

XTRA:HPHA

€139.8m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Zealand Pharma A/S Approves Appointments to the Board

Zealand Pharma A/S Announces Board Changes

Zealand Pharma A/S Announces Boehringer Ingelheim Survodutide Phase 2 Trial Shows 83% of Adults Treated a Statistically Significant Improvement of Metabolic Dysfunction-Associated Steatohepatitis

Zealand Pharma A/S, Annual General Meeting, Mar 20, 2024

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Recent updates

Zealand Pharma A/S Approves Appointments to the Board

Zealand Pharma A/S Announces Board Changes

Zealand Pharma A/S Announces Boehringer Ingelheim Survodutide Phase 2 Trial Shows 83% of Adults Treated a Statistically Significant Improvement of Metabolic Dysfunction-Associated Steatohepatitis

Zealand Pharma A/S, Annual General Meeting, Mar 20, 2024

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S Appoints Enrique Conterno and Elaine Sullivan as Board Observers

Zealand Pharma A/S to Report Q1, 2024 Results on May 16, 2024

Boehringer Ingelheim and Zealand Pharma A/S Announces Initiation of Three Phase III Trials

Zealand Pharma A/S Announces Designation of Priority Review by the US FDA for Dasiglucagon in Congital Hyperinsulinism

Zealand Pharma A/S Announces Positive Results from Part 1 of Multiple Ascending Dosing Trial with Amylin Analog ZP8396

Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency

Boehringer Ingelheim and Zealand Pharma A/S Announces Phase II Trial Showed 14.9% Weight Loss in People Living with Obesity or Unveil

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 786.05 million.

Zealand Pharma A/S Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (Ease 1)

Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism At the 60Th Annual Espe Meeting

Zealand Pharma A/S Announces Chief Financial Officer Changes

Zealand Pharma A/S Revises Revenue Guidance for the Full Year of 2022

Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the Nasdaq Global Select Market

Zealand Pharma A/S Presents Data from Phase 1 Trial of Dapiglutide and to Move into Phase 2 Trial for Obesity

Zealand Pharma Announces Appoints David M. Kendall, as Chief Medical Officer

Zealand Pharma A/S Announces Positive Top-Line Results from Its Second Phase 3 Clinical Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism

Zealand Pharma A/S (CPSE:ZEAL) entered into an agreement to acquire V-Go® Insulin Delivery Device from Zealand Pharma for $10 million.

Zealand Pharma Announces CEO Changes

Zealand Pharma A/S Announces Completion of Patient Enrollment in the Second Phase 3-Trial, 17103 in Children with Congenital Hyperinsulinism

Zealand Pharma Completes Enrollment in Ease-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma A/S announced that it expects to receive $200 million in funding from Oberland Capital Management LLC

Zealand Pharma Announces Successful Outcome of Phase 1B Clinical Trial with GLP1-GLP2 Dual Receptor Agonist, Dapiglutide

Zealand Pharma A/S Presents Data At 2021 ESPEN Virtual Congress Demonstrating Dose-Dependent Effects of Glepaglutide in Both Small and Large Intestines of Animal Models –in Contrast to Short-Acting GLP-2

Zealand Pharma Announces First Patient Dosed in EASE-SBS 4 Phase 3b Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Protagonist Therapeutics, Inc Announces Resolution of Contract Dispute with Zealand Pharma

Zealand Pharma Announces U.S. Commercial Availability of Zegalogue (Dasiglucagon) Injection

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

Zealand Pharma A/S Receives First FDA Approval and Prepares for Launch of Zegalogue® (Dasiglucagon) Injection

Zealand Pharma A/S Reaffirms Earnings Guidance for the Full Year of 2021

Zealand Pharma A/S Announces Publication of Phase 3 Trial Evaluating Efficacy and Safety of Dasiglucagon for Treatment of Severe Hypoglycemia in Adult Patients with Diabetes

Zealand Pharma A/S Announces Data from the First Phase 3-Trial with Dasiglucagon in Congenital Hyperinsulinism (Chi)

Zealand Pharma A/S to Report Q3, 2021 Results on Nov 11, 2021

Zealand Pharma Continues to Advance Clinical Programs and Commercial Launch Capabilities

Zealand Pharma A/S (CPSE:ZEAL) completed the acquisition of substantially all assets of Valeritas Holdings, Inc.

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Zealand Pharma A/S

36.3x

-9.0x

Beneficios e Ingresos